Tag Archives: LLY

Best High Tech Stocks To Watch For 2019

REPO (CURRENCY:REPO) traded down 8.1% against the US dollar during the twenty-four hour period ending at 0:00 AM Eastern on June 26th. In the last seven days, REPO has traded down 23.2% against the US dollar. One REPO token can now be bought for $0.0785 or 0.00001295 BTC on cryptocurrency exchanges. REPO has a total market capitalization of $0.00 and approximately $0.00 worth of REPO was traded on exchanges in the last day.

Here’s how other cryptocurrencies have performed in the last day:

Get REPO alerts:

XRP (XRP) traded 6.7% lower against the dollar and now trades at $0.52 or 0.00008331 BTC. Ripple (XRP) traded 5% lower against the dollar and now trades at $0.46 or 0.00007532 BTC. Stellar (XLM) traded 5.7% lower against the dollar and now trades at $0.18 or 0.00003035 BTC. Tether (USDT) traded down 0.4% against the dollar and now trades at $1.00 or 0.00016452 BTC. IOTA (MIOTA) traded down 7.5% against the dollar and now trades at $0.93 or 0.00015393 BTC. TRON (TRX) traded down 8.3% against the dollar and now trades at $0.0379 or 0.00000625 BTC. NEO (NEO) traded 5.2% lower against the dollar and now trades at $29.90 or 0.00493453 BTC. Binance Coin (BNB) traded 4.8% lower against the dollar and now trades at $14.03 or 0.00231574 BTC. VeChain (VET) traded 6.9% lower against the dollar and now trades at $2.48 or 0.00040943 BTC. Ontology (ONT) traded 7.7% lower against the dollar and now trades at $5.11 or 0.00084407 BTC.

REPO Token Profile

Best High Tech Stocks To Watch For 2019: Towerstream Corporation(TWER)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Global Eagle Entertainment (OTCMKTS: TWER) and Towerstream (OTCMKTS:TWER) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, analyst recommendations, risk, earnings and profitability.

  • [By Max Byerly]

    Magyar Telekom Tavkozlesi Nyrt (OTCMKTS:MYTAY) and Towerstream (OTCMKTS:TWER) are both small-cap utilities companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, profitability, institutional ownership and valuation.

Best High Tech Stocks To Watch For 2019: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Cory Renauer]

    Shares of Array BioPharma (NASDAQ:ARRY), an oncology-focused biopharmaceutical company, rose 31% in January, according to data from S&P Global Market Intelligence. Last month, Eli Lilly (NYSE:LLY) agreed to pay $8 billion for a few drugs that Array still owns a piece of. Also, a combination therapy Array already markets took a big step toward an important label expansion.

  • [By Todd Campbell]

    Nektar Therapeutics is also working with Eli Lilly (NYSE:LLY) on NKTR-358, a potential treatment for autoimmune diseases that’s in phase 1 trials. Last summer, Lilly paid $150 million up front, and it agreed to pay up to $250 million on additional development and regulatory milestones to work with Nektar Therapeutics on the drug.

  • [By JJ Kinahan]

    In addition to reports from T and VZ, these are some of the other major companies reporting earnings this week:

    Caterpillar Inc. (NYSE: CAT) and Eli Lilly and Co. (NYSE: LLY) report before market open on Tuesday, Apr. 24
    Boeing Co (NYSE: BA) reports before the open on Wednesday, Apr. 25
    Twitter Inc. (NYSE: TWTR) reports before the open Wednesday, Apr. 25 and Facebook, Inc. (NASDAQ: FB) reports after the close the same day
    Ford Motor Company (NYSE: F) reports after market close Wednesday, Apr. 25 and General Motors Company (NYSE: GM) reports before the open Thursday, Apr. 26
    Amazon.com, Inc. (NASDAQ: AMZN), Intel Corporation (NASDAQ: INTC) and Microsoft Corporation (NASDAQ: MSFT) all report after market close Thursday, Apr. 26
    Chevron Corporation (NYSE: CVX) and Exxon Mobil Corporation (NYSE: XOM) report before the open Friday, Apr. 27

    Information from TDA is not intended to be investment advice or construed as a recommendation or endorsement of any particular investment or investment strategy, and is for illustrative purposes only. Be sure to understand all risks involved with each strategy, including commission costs, before attempting to place any trade.

  • [By ]

    Only a few days later, on Jan. 7, Eli Lilly (NYSE: LLY) said it was buying Loxo Oncology (Nasdaq: LOXO) in an all-cash deal. The price tag: $8 billion. The reason is — you guessed it — LOXO’s cancer pipeline. The deal is intended to strengthen Lilly’s cancer-market efforts and to broaden its treatment portfolio.

  • [By ]

    Booker’s report took on other companies as well. Pfizer (PFE) , Gilead Sciences (GILD) , AbbVie  (ABBV) , Amgen (AMGN) , Bristol-Myers Squibb (BMY) Eli Lilly & Co. (LLY) , and Mylan NV (MYL) are cited for everything from raising drug prices, to stock buybacks and putting shareholder interest before that of the public.

Best High Tech Stocks To Watch For 2019: Western Asset Municipal High Income Fund, Inc.(MHF)

Advisors’ Opinion:

  • [By Max Byerly]

    Vivaldi Capital Management LLC increased its stake in Western Asset Municipal (NYSE:MHF) by 64.7% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 32,185 shares of the financial services provider’s stock after purchasing an additional 12,646 shares during the quarter. Vivaldi Capital Management LLC owned about 0.15% of Western Asset Municipal worth $231,000 at the end of the most recent quarter.

Top 10 High Tech Stocks To Buy For 2019

COB and CEO of Facebook Inc (NASDAQ:FB) Mark Zuckerberg sold 248,984 shares of FB on 08/15/2017 at an average price of $170.69 a share. The total sale was $42.5 million.

Facebook Inc is the world’s largest online social network. Its products are Facebook, Instagram, Messenger, WhatsApp, and Oculus. Its products enable people to connect and share through mobile devices and personal computers. Facebook Inc has a market cap of $493.71 billion; its shares were traded at around $170.00 with a P/E ratio of 36.78 and P/S ratio of 15.12. Facebook Inc had annual average EBITDA growth of 40.60% over the past five years.

CEO Recent Trades:

COB and CEO, 10% Owner Mark Zuckerberg sold 248,984 shares of FB stock on 08/15/2017 at the average price of $170.69. The price of the stock has decreased by 0.4% since.

Directors and Officers Recent Trades:

VP Marketing & Bus. Part. David B. Fischer sold 50,533 shares of FB stock on 08/10/2017 at the average price of $169.95. The price of the stock has increased by 0.03% since.VP and General Counsel Colin Stretch sold 750 shares of FB stock on 08/08/2017 at the average price of $171.88. The price of the stock has decreased by 1.09% since.Chief Technology Officer Michael Todd Schroepfer sold 37,963 shares of FB stock on 08/08/2017 at the average price of $171.98. The price of the stock has decreased by 1.15% since.Chief Product Officer Christopher K Cox sold 16,000 shares of FB stock on 08/07/2017 at the average price of $169.95. The price of the stock has increased by 0.03% since.VP and General Counsel Colin Stretch sold 750 shares of FB stock on 08/01/2017 at the average price of $169.93. The price of the stock has increased by 0.04% since.

For the complete insider trading history of FB, click here

Top 10 High Tech Stocks To Buy For 2019: Oriental Financial Group Inc.(OFG)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Engineers Gate Manager LP increased its stake in shares of OFG Bancorp (NYSE:OFG) by 62.7% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 76,455 shares of the bank’s stock after buying an additional 29,451 shares during the period. Engineers Gate Manager LP’s holdings in OFG Bancorp were worth $799,000 at the end of the most recent quarter.

  • [By Logan Wallace]

    Bank of Marin Bancorp (NASDAQ: BMRC) and OFG Bancorp (NYSE:OFG) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.

  • [By Joseph Griffin]

    Stevens Capital Management LP purchased a new stake in shares of OFG Bancorp (NYSE:OFG) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 16,250 shares of the bank’s stock, valued at approximately $170,000.

  • [By Ethan Ryder]

    OFG Bancorp (NYSE:OFG) will release its earnings data before the market opens on Friday, July 20th. Analysts expect OFG Bancorp to post earnings of $0.23 per share for the quarter.

  • [By Max Byerly]

    Shares of OFG Bancorp (NYSE:OFG) dropped 6.3% during trading on Monday . The company traded as low as $16.45 and last traded at $16.50. Approximately 794,358 shares changed hands during mid-day trading, an increase of 153% from the average daily volume of 313,807 shares. The stock had previously closed at $17.60.

  • [By Lisa Levin]

    Friday afternoon, the financial shares climbed 0.11 percent. Meanwhile, top gainers in the sector included Farmers Capital Bank Corporation (NASDAQ: FFKT), up 16 percent, and OFG Bancorp (NYSE: OFG), up 10 percent.

Top 10 High Tech Stocks To Buy For 2019: Proteon Therapeutics, Inc.(PRTO)

Advisors’ Opinion:

  • [By Max Byerly]

    Proteon Therapeutics (NASDAQ: PRTO) and Neurocrine Biosciences (NASDAQ:NBIX) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Top 10 High Tech Stocks To Buy For 2019: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Keith Speights]

    Dividend Yield

    Abbott Laboratories (NYSE:ABT) Drugs $109 billion 19.37 1.88%
    AstraZeneca (NYSE: AZN) Drugs $93 billion 19.70 3.97%
    Becton Dickinson and Co. (NYSE: BDX) Medical supplies $60 billion 17.74 1.29%
    DexCom (NASDAQ: DXCM) Medical devices $8 billion N/A N/A
    Eli Lilly and Co. (NYSE: LLY) Drugs $85 billion 14.91 2.77%
    Insulet (NASDAQ: PODD) Medical devices $5 billion 273.03 N/A
    Johnson & Johnson (NYSE: JNJ) Drugs, medical devices $325 billion 14.16 2.57%
    Lexicon Pharmaceuticals (NASDAQ:LXRX) Drugs $1 billion N/A N/A
    MannKind (NASDAQ: MNKD) Drugs $270 million N/A N/A
    Medtronic (NYSE: MDT) Medical devices $117 billion 15.36 2.14%
    Merck & Co. (NYSE: MRK) Drugs $159 billion 12.99 3.22%
    Novo Nordisk (NYSE:NVO) Drugs $116 billion 18.29 2.61%
    Pfizer (NYSE: PFE) Drugs $209 billion 11.62 3.82%
    Regeneron Pharmaceuticals (NASDAQ: REGN) Drugs $32 billion 13.95 N/A
    Sanofi (NYSE: SNY) Drugs $95 billion 10.75 4.64%
    Senseonics Holdings (NYSEMKT: SENS) Medical devices $447 million N/A N/A
    Tandem Diabetes Care (NASDAQ: TNDM) Medical devices $711 million N/A N/A

    Data source: Yahoo! Finance. P/E = price-to-earnings ratio; N/A = not applicable. Data as of May 25, 2018.

  • [By Jon C. Ogg]

    Eli Lilly and Co. (NYSE: LLY) also has a Neutral rating, and it was trading at $105.00. Merrill Lynch raised its price objective to $106 from $101, and the consensus analyst target price is $97.13.

  • [By Chris Lange]

    Eli Lilly and Co.’s (NYSE: LLY) short interest decreased to 12.64 million shares from the previous 14.20 million. The stock was trading at $106.21. The 52-week range is $73.69 to $107.84.

  • [By Chris Lange]

    Eli Lilly and Co. (NYSE: LLY) is set to report its most recent results Tuesday morning as well. The analysts’ consensus estimates are $1.14 in EPS on revenue of $5.49 billion. Shares were changing hands at $79.06 on Friday’s close. The consensus price target is $90.80, and the 52-week range is $73.69 to $89.09.

  • [By Ethan Ryder]

    Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 92,447 shares of the company’s stock in a transaction that occurred on Thursday, September 27th. The shares were sold at an average price of $107.00, for a total value of $9,891,829.00. Following the completion of the sale, the insider now owns 119,508,357 shares in the company, valued at approximately $12,787,394,199. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

  • [By Motley Fool Staff]

    Eli Lilly & Co. (NYSE:LLY) is a Goliath in diabetes treatment, and thanks to new drugs that can help patients control their disease better, the company’s diabetes sales are soaring.

Top 10 High Tech Stocks To Buy For 2019: Bellerophon Therapeutics, Inc.(BLPH)

Advisors’ Opinion:

  • [By Shane Hupp]

    Radius Health (NASDAQ:RDUS) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, earnings, risk, valuation, analyst recommendations, profitability and institutional ownership.

  • [By Money Morning Staff Reports]

    However, it’s unlikely Netlist repeats these returns anytime soon. After looking at last week’s top performing penny stocks, we’ll show you a penny stock on the verge of jumping over 230%…

    Penny Stock Current Share Price Last Week’s Gain
    Netlist Inc. (Nasdaq: NLST) $0.83 542.67%
    Mannkind Corp. (Nasdaq: MNKD) $1.80 79.09%
    Fred’s Inc. (Nasdaq: FRED) $2.49 73.68%
    Delcath Systems Inc. (OTCMKTS: DCTH) $3.70 72.63%
    Gemphire Therapeutics Inc. (Nasdaq: GEMP) $1.96 50.71%
    Bellerophon Therapeutics Inc. (Nasdaq: BLPH) $1.05 47.98%
    Cel-Sci Corp. (NYSE: CVM) $3.78 44.78%
    ParkerVision Inc. (OTCMKTS: PRKR) $0.60 29.42%
    Superior Drilling Products Inc. (NYSE: SDPI) $2.63 29.23%
    LiqTech International Inc. (NYSE: LIQT) $1.50 25.20%

    How to Profit off This $11.1 Billion Money Pool: By following a few simple steps, one IRS directive could help set you up to receive checks of up to $1,795 every single month thanks to a genius investment. Learn more…

  • [By Stephan Byrd]

    Press coverage about Bellerophon Therapeutics (NASDAQ:BLPH) has trended somewhat positive on Thursday, according to Accern. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Bellerophon Therapeutics earned a news impact score of 0.14 on Accern’s scale. Accern also assigned media stories about the biotechnology company an impact score of 46.948363531679 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

Top 10 High Tech Stocks To Buy For 2019: Tejon Ranch Co(TRC)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Terracoin (CURRENCY:TRC) traded down 14.6% against the dollar during the 24 hour period ending at 23:00 PM ET on May 17th. In the last week, Terracoin has traded 20.7% higher against the dollar. Terracoin has a market cap of $4.06 million and $4,377.00 worth of Terracoin was traded on exchanges in the last 24 hours. One Terracoin coin can now be bought for about $0.18 or 0.00002218 BTC on popular exchanges including CoinExchange, Trade Satoshi, C-CEX and Cryptopia.

  • [By Ethan Ryder]

    Terracoin (CURRENCY:TRC) traded up 10% against the dollar during the twenty-four hour period ending at 11:00 AM E.T. on October 8th. Terracoin has a total market cap of $2.09 million and approximately $4,720.00 worth of Terracoin was traded on exchanges in the last day. In the last seven days, Terracoin has traded down 15.3% against the dollar. One Terracoin coin can currently be bought for approximately $0.0910 or 0.00001375 BTC on popular exchanges including Trade Satoshi, CoinExchange, Cryptopia and C-CEX.

Top 10 High Tech Stocks To Buy For 2019: Orchids Paper Products Company(TIS)

Advisors’ Opinion:

  • [By Money Morning Staff Reports]

    After looking at last week’s top-performing penny stocks, we’ll show you a penny stock on the verge of jumping over 159%…

    Penny Stock Current Share Price Last Week’s Gain
    My Size Inc. (NASDAQ: MYSZ) $1.19 60.71%
    Delcath Systems Inc. (OTCMKTS: DCTH) $3.21 52.38%
    Regional Health Properties Inc. (NYSE: RHE) $0.18 49.39%
    Nemaura Medical Inc. (NASDAQ: NMRD) $3.03 44.89%
    3Pea International Inc. (NASDAQ: TPNL) $4.62 42.24%
    PLx Pharma Inc. (NASDAQ: PLXP) $4.22 34.38%
    Orchids Paper Products Co. (NYSE: TIS) $3.99 34.30%
    DelMar Pharmaceuticals Inc. (NASDAQ: DMPI) $0.74 33.41%
    Restoration Robotics Inc. (NASDAQ: HAIR) $3.08 32.74%
    Renren Inc. (NYSE: RENN) $1.69 32.61%

    Don’t Miss Out: The Treasury is sitting on an $11.1 billion cash pile, and a loophole entitles Americans to a sizable portion. Some are collecting $1,795, $3,000, or $5,000 every month thanks to this powerful investment…

  • [By Paul Ausick]

    Orchids Paper Products Co. (NYSEAMERICAN: TIS) dropped more than 12% Monday to set a new 52-week low of $0.70. Shares closed at $0.80 on Friday and the stock’s 52-week high is $15.47. Volume totaled around 15 million, about 60 times the daily average of around 250,000. The company had no specific news. Shares have made a massive comeback and are on track to close at $2.47, up more than 200%.

  • [By Lisa Levin]

      

    Clearside Biomedical, Inc. (NASDAQ: CLSD) shares declined 32.19 percent to close at $9.86 on Thursday. Clearside Biomedical disclosed that its Phase 2 trial of CLS-TA met primary and secondary endpoints met in 6-month trial.
    scPharmaceuticals Inc. (NASDAQ: SCPH) shares dipped 30.1 percent to close at $9.94 on Thursday after the FDA identified deficiencies in the company’s New Drug Application for FUROSCIX. However, the FDA letter did not specify deficiencies identified and notification does not reflect final decision on information under review.
    Euroseas Ltd. (NASDAQ: ESEA) fell 24.08 percent to close at $1.86. Euroseas announced completion of the spin-off of its drybulk fleet into EuroDry Ltd.
    Golar LNG Limited (NASDAQ: GLNG) fell 25.09 percent to close at $25.98 following Q1 results.
    Oragenics, Inc. (NASDAQ: OGEN) shares dropped 25 percent to close at $1.50 on Thursday.
    Guess', Inc. (NYSE: GES) dropped 19.44 percent to close at $19.60 following Q1 results.
    Cantel Medical Corp. (NYSE: CMD) dropped 15.94 percent to close at $109.09 on Thursday following FQ3 results.
    Fusion Connect, Inc. (NASDAQ: FSNN) shares fell 15.55 percent to close at $3.91.
    Build-A-Bear Workshop, Inc. (NYSE: BBW) dropped 14.44 percent to close at $8.00 after reporting Q1 results.
    Dollar Tree, Inc. (NASDAQ: DLTR) shares declined 14.28 percent to close at $82.59 after the company reported weaker-than-expected earnings for its first quarter and lowered its FY2018 earnings guidance.
    Titan Machinery Inc. (NASDAQ: TITN) dropped 13.94 percent to close at $18.09 after reporting Q1 results.
    Co-Diagnostics, Inc. (NASDAQ: CODX) declined 13.17 percent to close at $2.90 after declining 5.65 percent on Wednesday.
    Concordia International Corp. (NASDAQ: CXRX) fell 12.89 percent to close at $0.2440 after the company announced that it would be delisted from the Nasdaq.
    Sears Holdings Corporation (NASDAQ: SHLD) slipped 12.46 percent

  • [By Lisa Levin] Gainers
    SemiLEDs Corporation (NASDAQ: LEDS) shares rose 35.8 percent to $4.55.
    EVINE Live Inc. (NASDAQ: EVLV) gained 28.8 percent to $1.04. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet.
    Sanmina Corp (NASDAQ: SANM) shares surged 19.1 percent to $33.00 as the company reported stronger-than-expected earnings for its second quarter on Monday.
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) gained 14.9 percent to $37.22 as the company posted upbeat results for its first quarter.
    Santander Consumer USA Holdings Inc. (NYSE: SC) shares climbed 14 percent to $17.90 following upbeat quarterly earnings.
    Helix Energy Solutions Group, Inc. (NYSE: HLX) climbed 14 percent to $7.12 following strong quarterly results.
    Check-Cap Ltd. (NASDAQ: CHEK) gained 13.6 percent to $8.25.
    Atossa Genetics Inc. (NASDAQ: ATOS) rose 11.8 percent to $3.34. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men.
    Cadence Design Systems, Inc. (NASDAQ: CDNS) gained 11.6 percent to $40.99 after the company posted upbeat Q1 results and issued a strong Q2 forecast.
    Genprex, Inc. (NASDAQ: GNPX) climbed 11.2 percent to $4.9363.
    Mitel Networks Corporation (NASDAQ: MITL) rose 10.5 percent to $11.23 after the company agreed to be acquired by affiliates of Searchlight Capital Partners for $2.0 billion.
    Systemax Inc. (NYSE: SYX) rose 10.2 percent to $30.86. Sidoti & Co. upgraded Systemax from Neutral to Buy.
    Orchids Paper Products Company (NYSE: TIS) surged 9.2 percent to $7.13. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018.
    New Oriental Education & Technology Group Inc. (NYSE: EDU) rose
  • [By Lisa Levin] Gainers
    Check-Cap Ltd. (NASDAQ: CHEK) shares jumped 104.82 percent to close at $14.87 on Tuesday.
    EVINE Live Inc. (NASDAQ: EVLV) rose 31.25 percent to close at $1.06. The pay-TV home shopping company was named as a potential acquisition target by TechCrunch. According to the publication, Amazon.com, Inc. (NASDAQ: AMZN) is exploring ways of marketing its products and services to consumers beyond the internet.
    SemiLEDs Corporation (NASDAQ: LEDS) shares climbed 27.16 percent to close at $4.26 on Tuesday.
    Atossa Genetics Inc. (NASDAQ: ATOS) gained 27.09 percent to close at $3.80. Atossa Genetics disclosed that it has Received positive interim review from the Independent Safety Committee in Phase 1 Topical endoxifen dose escalation study in men.
    Heidrick & Struggles International, Inc. (NASDAQ: HSII) surged 17.13 percent to close at $37.95 as the company posted upbeat results for its first quarter.
    Santander Consumer USA Holdings Inc. (NYSE: SC) shares gained 15.91 percent to close at $18.21 following upbeat quarterly earnings.
    Riot Blockchain, Inc. (NASDAQ: RIOT) shares jumped 15.73 percent to close at $7.58 on Tuesday after declining 1.50 percent on Monday.
    Sanmina Corp (NASDAQ: SANM) shares gained 14.62 percent to close at $31.75 as the company reported stronger-than-expected earnings for its second quarter on Monday.
    Orchids Paper Products Company (NYSE: TIS) jumped 12.86 percent to close at $7.37. Orchids Paper Products is expected to report its Q1 financial results on Wednesday, April 25, 2018.
    Helix Energy Solutions Group, Inc. (NYSE: HLX) rose 12.8 percent to close at $7.05 following strong quarterly results.
    Avid Bioservices, Inc. (NASDAQ: CDMO) rose 12.72 percent to close at $3.81.
    Genprex, Inc. (NASDAQ: GNPX) gained 12.61 percent to close at $5.00.
    Obalon Therapeutics, Inc. (NASDAQ: OBLN) rose 12.39 percent to close at $3.72.
    NextDecade Corporation (NASDAQ: NEXT) shares climbed 11.88 percent to close at $7
  • [By Money Morning Staff Reports]

    Last week’s top performing penny stock, Orchids Paper Products Co. (NYSE: TIS), jumped over 218% after the company delivered a stellar earnings reports on Aug. 13.

Top 10 High Tech Stocks To Buy For 2019: Intercontinental Exchange Inc.(ICE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Canlan Ice Sports Corp (TSE:ICE) declared a quarterly dividend on Friday, August 10th, Zacks reports. Stockholders of record on Friday, September 28th will be paid a dividend of 0.025 per share on Tuesday, October 16th. This represents a $0.10 annualized dividend and a dividend yield of 2.01%. The ex-dividend date of this dividend is Thursday, September 27th. This is an increase from Canlan Ice Sports’s previous quarterly dividend of $0.02.

  • [By Joseph Griffin]

    Shares of Intercontinental Exchange (NYSE:ICE) have earned an average recommendation of “Buy” from the sixteen brokerages that are presently covering the stock, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $78.36.

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on Intercontinental Exchange (ICE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Shane Hupp]

    OTC Markets Group (OTCMKTS:OTCM) and Intercontinental Exchange (NYSE:ICE) are both finance companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, analyst recommendations, institutional ownership, profitability and dividends.

Top 10 High Tech Stocks To Buy For 2019: Cullen/Frost Bankers, Inc.(CFR)

Advisors’ Opinion:

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Cullen/Frost Bankers (CFR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Jordan Wathen, Matthew Frankel, CFP, and Dan Caplinger]

    Below, three Motley Fool contributors lay the case for Cullen/Frost Bankers (NYSE:CFR), Morgan Stanley (NYSE:MS), and Synchrony Financial (NYSE:SYF) as ways to profit from a rising tide for bank stocks.

  • [By Anders Bylund, Jason Hall, Danny Vena, Jordan Wathen, and Brian Feroldi]

    In that spirit, we asked a few of our Motley Fool investors what they see as the best investment ideas at the start of July, 2018. They were quick to suggest Chinese e-commerce giant Baidu (NASDAQ:BIDU), coffee giant Starbucks (NASDAQ:SBUX), clean energy specialist TerraForm Power (NASDAQ:TERP), semiconductor veteran Intel, (NASDAQ:INTC), and Texan bank Cullen/Frost Bankers (NYSE:CFR).

  • [By Brian Feroldi]

    Cullen/Frost Bankers (NYSE:CFR), a regional bank based in Texas, reported its second-quarter results on Thursday, July 26. A favorable lending environment combined with rising interest rates to drive earnings-per-share growth of 30%.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Cullen/Frost Bankers (CFR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    News articles about Cullen/Frost Bankers (NYSE:CFR) have been trending somewhat positive on Saturday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Cullen/Frost Bankers earned a news sentiment score of 0.01 on Accern’s scale. Accern also assigned news stories about the bank an impact score of 46.1866283388257 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top 10 High Tech Stocks To Buy For 2019: Guidewire Software, Inc.(GWRE)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Guidewire Software (NYSE:GWRE) is scheduled to be announcing its earnings results after the market closes on Wednesday, September 5th. Analysts expect the company to announce earnings of $0.54 per share for the quarter.

  • [By Garrett Baldwin]

    Starbuck’s Corp. (Nasdaq: SBUX) Executive Chair Howard Schultz announced he will depart the company. Many are speculating he will pursue a career in politics and potentially seek the Democratic nomination for president in 2020. Schultz had previously denied any speculation around a role in government; but his recent comments suggest that “public service” will be a part of his future plans. Gold prices dipped below $1,300 per ounce as markets continue to speculate on the likelihood of additional interest rate hikes in 2018. We believe this is solid buying opportunity for investors. The reason why gold is going to get a nice boost: ongoing trade tensions between the United States and the rest of the globe. Money Morning Resource Specialist Peter Krauth provides his insight on where gold prices are heading next and how you can make big gains in the weeks ahead.
    Three Stocks to Watch Today: AAPL, TWTR, SCGLF
    Apple Inc. (Nasdaq: AAPL) is on the verge of becoming the world’s first $1 trillion company. The stock pushed above $192.60 per share in pre-market hours after its first day at the Worldwide Developers Conference. During the event, the company unveiled its new mobile operating system, called iOS 12. The firm also unveiled a suite of tools designed to combat technology addiction. Shares of Twitter Inc. (NYSE: TWTR) jumped nearly 4% on news that the social media company is about to join the S&P 500. The company will join on Thursday morning and will replace agribusiness giant Monsanto Co. (NYSE: MON). The news comes as Monsanto is in the final steps of its merger with German chemical giant Bayer AG (Nasdaq: BAYRY). Shares of Societe Generale SA (ADR) (OTCMKTS: SCGLF) are in focus after the U.S. Justice Department announced the French investment bank will pay $1.3 billion to settle two ongoing legal headaches. The company bribed Libyan officials and manipulated LIBOR, a benchmark interest rate on which most financing is based. Legg Mason Inc. (NYSE: L

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Guidewire Software (GWRE)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Guidewire Software Inc (NYSE:GWRE) shares reached a new 52-week high and low during mid-day trading on Wednesday . The company traded as low as $95.26 and last traded at $93.56, with a volume of 7356 shares changing hands. The stock had previously closed at $94.77.

Top 10 High Tech Stocks To Buy For 2019: Apricus Biosciences, Inc(APRI)

Advisors’ Opinion:

  • [By Chris Lange]

    Apricus Biosciences Inc. (NASDAQ: APRI) has a PDUFA goal date for completion of the FDA’s review of the Vitaros NDA set on February 17. Vitaros is a novel, on-demand topical cream for the treatment of erectile dysfunction (ED) and a new potential entrant into the U.S. ED treatment market. So far Vitaros has been approved in Canada, Mexico and certain countries in Europe, Latin America and the Middle East. Shares of Apricus were last seen at $2.22, with a 52-week range of $0.86 to $3.49 and a consensus price target of $3.50.

  • [By Paul Ausick]

    Apricus Biosciences Inc. (NASDAQ: APRI) also dropped about 38% Monday to post a new 52-week low of $0.26. Shares closed at $0.42 on Friday and the stock’s 52-week high is $3.34. Volume was more than three times the daily average of around 1.4 million shares. The company is considering its options after the U.S. FDA directed the firm to develop a new formulation for its erectile dysfunction drug, Vitaros.

  • [By Alexander Bird]

    Here are last week’s top-performing penny stocks:

    Penny Stock Current Share Price Last Week’s Gain
     Ambow Education Holdings Ltd. (NYSE: AMBO) $5.70 77.11%
    Nano Dimension (Nasdaq: NNDM) $2.61 75.11%
    Destination Maternity Corp. (Nasdaq: DEST) $5.79 71.84%
    CLPS Inc. (Nasdaq: CLPS) $9.72 71.15%
    NII Holdings Inc. (Nasdaq: NIHD) $3.20 56.33%
    Viveve Medical Inc. (Nasdaq: VIVE) $3.78 51.98%
    Galectin Therapeutics Inc. (Nasdaq: GALT) $9.18 41.82%
    Apricus Biosciences Inc. (Nasdaq: APRI) $0.36 34.70%
    Polymet Mining Corp. (NYSE: PLM) $1.01 31.13%
    Xenon Pharmaceuticals Inc. (Nasdaq: XENE) $8.20 28.46%

    Many investors struggle with finding stocks with this sort of breakout potential because they don’t know where to look.

  • [By William Romov]

    California-based Apricus Biosciences Inc. (Nasdaq: APRI) develops treatments in the areas of urology and rheumatology. Its lead product, Vitaros, is a topically applied cream for the treatment of erectile dysfunction (ED).

Amgen’s Novel Migraine Treatment Gets Key Approval

Amgen Inc. (NASDAQ: AMGN) shares saw a nice bump after the U.S. Food and Drug Administration (FDA) on Thursday approved Aimovig (erenumab), Amgen’s preventive treatment of migraine in adults. It is the first FDA-approved preventive migraine treatment in a new class of drugs, which work by blocking the activity of calcitonin gene-related peptide, which is believed to play a critical role in migraine attacks.

Aimovig’s effectiveness in preventing migraines was evaluated in three clinical trials. The first two studies compared Aimovig to placebo in participants with a history of episodic migraine. Patients receiving Aimovig on average experienced one or two fewer monthly migraine days than those on placebo. The third study evaluated patients with a history of chronic migraine. Patients in that study treated with Aimovig averaged two and a half fewer monthly migraine days in three months than those receiving placebo.

The most common side effects that patients in the clinical trials reported were constipation and injection site reactions.

Preventive medications may be an option for around 8 million Americans suffering from migraine, Amgen said. Aimovig, which is given monthly by self-injection, will have a list price of $6,900 a year, or $575 a month, the company also said. Last week, President Donald Trump blasted drugmakers and health care middlemen for making prescription medicines unaffordable for Americans. Amgen, which will market Aimovig in partnership with Novartis A.G. (NYSE: NVS), said the drug’s price “reflects the value it brings to patients and society.”

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) and Eli Lilly & Co. (NYSE: LLY) are among companies developing similar treatments.

Stewart J. Tepper, MD, Professor of Neurology at the Geisel School of Medicine at Dartmouth Medical School, said:

Having a treatment designed to specifically address the complex nature of migraine is an important and welcome step forward in headache medicine. Aimovig offers self-administration with proven efficacy across a spectrum of patients, including in those who have previously tried other preventive therapies without success.

Shares of Amgen were up almost 2% at $177.56 in Fridays premarket, with a consensus analyst price target of $194.33 and a 52-week trading range of $152.16 to $201.23.

Novartis and Teva shares were up marginally in early indications as well.

24/7 Wall St.
UBS Makes Big Health Care Swap in Top Performing Q-GARP Portfolio

Top Gold Stocks To Invest In Right Now

There are several reasons why investors may want to add gold to their portfolio. Not only can gold rise in value over time, but it can be a hedge against inflation and can add diversification.

Having said that, gold doesn’t fit in to Warren Buffett’s investing philosophy. The central investing principle that has allowed Buffett to build Berkshire Hathaway (NYSE:BRK-A) (NYSE:BRK-B) into the massive conglomerate it is today excludes gold and most other assets that are considered to be stores of value.

Here’s a brief overview of Warren Buffett’s investment style, as well as his opinion on gold in particular, which should help paint a clear picture of why you shouldn’t expect to see gold bullion in Berkshire’s investment portfolio anytime soon.

Image source: The Motley Fool.

The short answer

Warren Buffett doesn’t invest in gold. There are three main things Warren Buffett does invest in, both with Berkshire Hathaway’s capital and his own money: entire companies, stocks of public companies, and cash equivalents that are waiting to be invested in those two. If you take a look at Berkshire’s investment portfolio, you’ll find plenty of subsidiary companies and stock investments, but gold is nowhere to be found.

Top Gold Stocks To Invest In Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By Keith Speights]

    One comparison tells a lot about the current situations for AbbVie Inc. (NYSE:ABBV) and Eli Lilly (NYSE:LLY). AbbVie stock has fallen more than 20% over the last month — and it’s still outperforming Lilly over the past 12 months and so far in 2018.

  • [By ]

    Pharmaceutical stocks joined the party Wednesday after Trump dredged up drug pricing concerns during his State of the Union address. Every major drug manufacturer retreated yesterday. Eli Lilly & Co. (NYSE:LLY) led the way lower with a decline of more than 5%. Johnson & Johnson (NYSE:JNJ) and AbbVie (NYSE:ABBV) werent far behind with losses of 3%.

  • [By ]

    Cramer and the AAP team say they’re trimming El Lilly (LLY) and adding WestRock (WRK) and Textron (TXT) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    Cramer and the AAP team weigh in on Eli Lilly’s (LLY) deal to buy ARMO BioSciences (ARMO) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By Chris Lange]

    When Eli Lilly and Co. (NYSE: LLY) released its most recent quarterly earnings report before the markets opened on Tuesday, the company said that it had $1.34 in earnings per share (EPS) on $5.7 billion in revenue. The consensus estimates had called for $1.14 in EPS on revenue of $5.49 billion. In the same period of last year, the drugmaker said it had EPS of $0.98 and $5.23 billion in revenue.

Top Gold Stocks To Invest In Right Now: Bruker Corporation(BRKR)

Advisors’ Opinion:

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Bruker (BRKR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Gold Stocks To Invest In Right Now: CarMax Inc(KMX)

Advisors’ Opinion:

  • [By ]

    Winners will collect specialized data, and their customers will understand why they are providing data. Among the companies that are already doing this is CarMax (NYSE: KMX).

  • [By Andy Pai]

    CarMax, Inc (NYSE: KMX) is the second most undervalued stock in the portfolio. The company's blended upside of 17.8 percent is very intriguing.

  • [By Trey Thoelcke]

    CarMax Inc. (NYSE: KMX) is set to release its most recent quarterly results first thing on Wednesday. The consensus forecast calls for $0.88 in EPS and $4.21 billion in revenue for the fiscal fourth quarter. Shares traded on Thursdays close at $61.94. The consensus price target is $77.71, and the 52-week range is $54.29 to $77.64.

  • [By Demitrios Kalogeropoulos]

    CarMax (NYSE:KMX) recently posted quarterly earnings results that were marked by a slowdown in sales growth. The used-car retailer endured a painful drop in customer traffic, which led sales to inch higher by less than 1% despite an aggressive expansion in its store base.

Top Gold Stocks To Invest In Right Now: Scorpio Tankers Inc.(STNG)

Advisors’ Opinion:

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Scorpio Tankers (STNG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Rich Smith]

    Stocks don’t always make sense — a factinvestors should be happy about afterScorpio Tankers (NYSE:STNG) posted a quarterly loss and an earnings miss this morning and then rocketed 15% in early trading.

  • [By Lisa Levin] Gainers
    Daré Bioscience, Inc. (NASDAQ: DARE) shares jumped 56.69 percent to close at $1.27 on Wednesday on news that the company entered into worldwide license agreement for Juniper Pharmaceuticals' intravaginal ring technology platform.
    Vicor Corporation (NASDAQ: VICR) rose 26.84 percent to close at $37.10. Vicor posted Q1 earnings of $0.10 per share on sales of $65.2 million.
    AGM Group Holdings Inc. (NASDAQ: AGMH) climbed 25.56 percent to close at $10.61.
    Travelzoo (NASDAQ: TZOO) gained 24.7 percent to close at $9.75 following strong Q1 results.
    Intrepid Potash, Inc. (NYSE: IPI) shares climbed 19.24 percent to close at $4.71.
    China Customer Relations Centers, Inc. (NASDAQ: CCRC) rose 18.73 percent to close at $18.64.
    Genprex, Inc. (NASDAQ: GNPX) climbed 18.28 percent to close at $5.89. Genprex expanded its operations to Cambridge, Mass.
    Scorpio Tankers Inc. (NYSE: STNG) rose 13.92 percent to close at $2.70 following Q1 results.
    Rocky Brands, Inc. (NASDAQ: RCKY) shares surged 13.57 percent to close at $23.85 after reporting Q1 results.
    Resonant Inc. (NASDAQ: RESN) shares rose 12.5 percent to close at $4.14 on Wednesday.
    USANA Health Sciences, Inc. (NYSE: USNA) jumped 11.24 percent to close at $106.85 following Q1 results.
    SUPERVALU Inc. (NYSE: SVU) rose 11.16 percent to close at $16.24 after the company reported Q4 results and agreed to sell and leaseback eight distribution centers for an aggregate purchase price of $483 million.
    K12 Inc. (NYSE: LRN) shares gained 10.74 percent to close at $15.36 following Q3 results.
    Tupperware Brands Corporation (NYSE: TUP) rose 9.15 percent to close at $46.28 as the company posted in-line quarterly earnings.
    Six Flags Entertainment Corporation (NYSE: SIX) shares climbed 8.49 percent to close at $64.18 as the company posted a narrower-than-expected loss for its first quarter.
    Carlisle Companies Incorporated (NYSE: CSL) gained 8.2 percent to close at $107.94 af
  • [By Lisa Levin]

    Wednesday afternoon, the energy shares gained 0.74 percent. Meanwhile, top gainers in the sector included Pengrowth Energy Corporation (NYSE: PGH), up 12 percent, and Scorpio Tankers Inc. (NYSE: STNG), up 12 percent.

Top Warren Buffett Stocks To Buy Right Now

Mining for cryptocurrency is getting tastier and paying off with a lot less electricity use. Kraft Heinz Co. (NASDAQ: KHC) last week launched a promotion that gives consumers an instant chance to win a “bacoin” currently valued at three slices of the company’s Oscar Mayer bacon.

After all the nasty things that Kraft Heinz’s main shareholder had to say this past weekend about cryptocurrencies, maybe Warren Buffett’s attitude will change if bacoins turn into a productive asset. Buffett’s Berkshire Hathaway Inc. (NYSE: BRK-B) owns a stake of about 27% in Kraft Heinz.

As much as the 87-year old Buffett doesn’t like digital currencies, Berkshire Vice-ChairCharlie Munger, who is 94, likes them even less:

To me, it’s just dementia. It’s like somebody else is trading turds and you decide you can’t be left out.

If you happen to win a bacoin, you get a chance to raise the value of the bacoin either by sharing a pre-set message to your Twitter followers or by providing the email addresses of three friends. There are some limitations, so read the rules for yourself.

Top Warren Buffett Stocks To Buy Right Now: Platform Specialty Products Corporation(PAH)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on Platform Specialty Products (PAH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Shares of Platform Specialty Products Co. (NYSE:PAH) have earned a consensus rating of “Hold” from the eight brokerages that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $14.40.

Top Warren Buffett Stocks To Buy Right Now: Nu Skin Enterprises Inc.(NUS)

Advisors’ Opinion:

  • [By ]

    Nu Skin Enterprises (NYSE: NUS) is benefiting from two key trends: its strong presence in Asia where it books 79% of its revenue and leading brand awareness with millennials. The company has increased its dividend every year since 2001, now paying a 2% yield, and maintains a share repurchase program that returns excess cash to shareholders.

Top Warren Buffett Stocks To Buy Right Now: 3D Systems Corporation(DDD)

Advisors’ Opinion:

  • [By Beth McKenna]

    As with last quarter, main rival 3D Systems(NYSE:DDD) is scheduled to report on the same day, though before the market opens.

    Shares of Stratasys are up 3.5% so far in 2018 through April 24. For context, the S&P 500 is down 1% in 2018, while 3D Systems stock has gained nearly 30% this year.

  • [By Chris Lange]

    3D Systems Corp. (NYSE: DDD) is set to release its most recent quarterly results on Wednesday. The consensus forecast calls for breakeven earnings and $164.7 million in revenue. Shares closed on Friday at $12.05. The consensus price target is $9.83, and the 52-week range is $7.92 to $23.70.

  • [By Paul Ausick]

    Short interest in 3D Systems Corp. (NYSE: DDD) fell by 1.9% to 35.03 million shares. Some 32.1% of the company’s float was short. Days to cover rose from 12 to 15. In the two-week short interest period, the share price rose by 27.3%. The stock’s 52-week trading range is $7.92 to $23.70, and shares closed at $10.68 on Wednesday, up about 0.7% on the day.

  • [By Demitrios Kalogeropoulos]

    Let’s see what we can expect from the companies set to release some of the most anticipated earnings reports: Lowe’s (NYSE:LOW), 3D Systems (NYSE:DDD), and TJX Companies (NYSE:TJX).

  • [By Beth McKenna]

    Diversified 3D printing company 3D Systems(NYSE:DDD) is slated to report its first-quarter 2018 earnings after the market closes on Wednesday, May 2. As with last quarter, main rivalStratasysis scheduled to report on the same day, though before the market opens.

Top Warren Buffett Stocks To Buy Right Now: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By ]

    Cramer and the AAP team say they’re trimming El Lilly (LLY) and adding WestRock (WRK) and Textron (TXT) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By ]

    In the Lightning Round, Cramer was bullish on Spotify (SPOT) , Alkermes (ALKS) , Johnson & Johnson (JNJ) , Thermo Fisher Scientific (TMO) , Sorrento Therapeutics (SRNE) , NVIDIA (NVDA) , Nucor, Eli Lilly (LLY) and Kohlberg Kravis Roberts (KKR) .

  • [By Chris Lange]

    Incyte Corp. (NASDAQ: INCY) and Eli Lilly and Co. (NYSE: LLY) will be under the microscope next week as the U.S. Food and Drug Administration (FDA) will decide the fate of their rheumatoid arthritis (RA) treatment.

  • [By Lisa Levin] Gainers
    ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share.
    Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook.
    vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June.
    Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results.
    RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results.
    Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million.
    Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter.
    Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales.
    Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings.
    MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma.
    New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor.
    Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session.
    Himax Technologies, Inc. (NASDAQ: HIMX) shares rose

Top Warren Buffett Stocks To Buy Right Now: Dell Technologies Inc. (DVMT)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Here are some of the news headlines that may have impacted Accern Sentiment Analysis’s analysis:

    Get Dell Technologies alerts:

    Dell launches Customer Solution Center in UAE (khaleejtimes.com) Hilal Computers selected for Dell EMC President’s Circle (arabnews.com) Dell Technologies Customer Solution Centre opens in Dubai (tahawultech.com) Dell Technologies launches new Customer Solution Centre in UAE (itp.net) Dell Technologies (DVMT) Downgraded by Zacks Investment Research to Hold (americanbankingnews.com)

    NYSE DVMT traded up $0.30 during mid-day trading on Wednesday, hitting $74.22. The stock had a trading volume of 830,865 shares, compared to its average volume of 2,081,792. Dell Technologies has a 52-week low of $73.19 and a 52-week high of $74.78. The company has a market capitalization of $56.67 billion, a P/E ratio of 12.03, a PEG ratio of 1.41 and a beta of -0.45. The company has a debt-to-equity ratio of 2.94, a current ratio of 0.85 and a quick ratio of 0.79.

  • [By Stephan Byrd]

    Meeder Asset Management Inc. decreased its position in Dell Technologies (NYSE:DVMT) by 89.4% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 1,948 shares of the company’s stock after selling 16,346 shares during the period. Meeder Asset Management Inc.’s holdings in Dell Technologies were worth $143,000 at the end of the most recent reporting period.

  • [By Money Morning Staff Reports]

    The 1,610 cryptocurrencies on CoinMarketCap.com have a total market cap of $404 billion, making them worth more than Twitter Inc. (NYSE: TWTR), Snap Inc. (NYSE: SNAP), International Business Machines Corp. (NYSE: IBM), and Dell Technologies Inc. (NYSE: DVMT) combined.

good stocks to invest in today

Related LVS 5 Trends U.S. Casino Investors Need To Watch Deutsche Bank Says Buy MGM Following SotP Analysis, 'Encouraging' Q4 Metrics Macau at the crossroads (Seeking Alpha)
Related Benzinga's Top Upgrades Morgan Stanley Revises Triple-Net REIT Ratings Prior To Q2 Earnings

One of the more unique technical analysis metrics used to determine buy and sell signals is Parabolic SAR. Developed by Welles Wilder in 1978, the “SAR” stands for “stop and reverse.”

good stocks to invest in today: Orchid Island Capital, Inc.(ORC)

Advisors’ Opinion:

  • [By Paul Ausick]

    Orchid Island Capital Inc. (NYSE: ORC) fell about 9.7% to post a new 52-week low of $7.85 Thursday after closing at $8.69 on Wednesday. The 52-week high is $12.60. Volume of about 5.2 million was nearly 5 times the daily average of around 1.1 million. The company lowered its monthly dividend by 3 cents last night.

good stocks to invest in today: Globe Specialty Metals Inc.(GSM)

Advisors’ Opinion:

  • [By Ethan Ryder]

    TRADEMARK VIOLATION WARNING: “$559.12 Million in Sales Expected for Ferroglobe (GSM) This Quarter” was originally published by Ticker Report and is the property of of Ticker Report. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3385662/559-12-million-in-sales-expected-for-ferroglobe-gsm-this-quarter.html.

good stocks to invest in today: Northern Trust Corporation(NTRS)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Northern Trust (NASDAQ:NTRS) insider Jeffrey D. Cohodes sold 14,979 shares of the firm’s stock in a transaction dated Monday, May 7th. The stock was sold at an average price of $105.15, for a total value of $1,575,041.85. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

  • [By Logan Wallace]

    Northern Trust (NASDAQ:NTRS)‘s stock had its “buy” rating reaffirmed by analysts at Royal Bank of Canada in a research report issued on Wednesday.

  • [By Ethan Ryder]

    Northern Trust (NASDAQ:NTRS) last announced its quarterly earnings results on Tuesday, April 17th. The asset manager reported $1.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.42 by $0.16. The firm had revenue of $1.48 billion during the quarter, compared to analyst estimates of $1.45 billion. Northern Trust had a return on equity of 13.87% and a net margin of 21.84%. Northern Trust’s quarterly revenue was up 14.8% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.09 earnings per share. analysts anticipate that Northern Trust will post 6.49 EPS for the current year.

good stocks to invest in today: HCP, Inc.(HCP)

Advisors’ Opinion:

  • [By Matthew Frankel]

    Healthcare real estate investment trust HCP (NYSE:HCP) hasn’t exactly been a high-performing stock recently. In fact, while the S&P 500 has risen 26% over the past two years, HCP has fallen 23%.

  • [By Reuben Gregg Brewer]

    The aging baby boomer generation is set to materially increase demand for senior housing. The question isn’t if but when because the demographic shifts this giant generation will engender are largely unavoidable. Investors looking at the senior housing sector have a number of options to pick from, with two of the biggest names in the space being HCP, Inc. (NYSE:HCP) and Brookdale Senior Living, Inc. (NYSE:BKD). But what’s the better choice here: the property owner or the facility manager?

good stocks to invest in today: Host Hotels & Resorts, Inc.(HST)

Advisors’ Opinion:

  • [By Logan Wallace]

    Host Hotels & Resorts (NYSE:HST) had its price objective boosted by Stifel Nicolaus from $20.50 to $21.00 in a research note published on Thursday. They currently have a buy rating on the real estate investment trust’s stock.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on Host Hotels & Resorts (HST)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

good stocks to invest in today: Eli Lilly and Company(LLY)

Advisors’ Opinion:

  • [By ]

    This week we get our first look at quarterly numbers from major drug and biotech giants such as AbbVie (ABBV)  , Amgen (AMGN)  , Biogen (BIIB) , Biomarin Pharmaceuticals (BMRN)  and Action Alerts PLUS holding Eli Lilly (LLY) , which all provide the market a glimpse of how the first quarter was for the industry over the next few days,” according to Real Money Pro columnist Bret Jensen.

  • [By ]

    Drug companies Eli Lilly (LLY) gained about 2%, Pfizer (PFE) added 1.3%, Abbott Laboratories (ABT) rose 1.2% and Bristol-Myers Squibb (BMY) advanced by 1.4% after the president promised lower list prices, less costs for patients and more competition among the drug makers.

  • [By Lisa Levin]

    ARMO BioSciences, Inc. (NASDAQ: ARMO) shares shot up 67 percent to $49.805 after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share.

  • [By ]

    AbbVie (ABBV) : “I want to stay away from controversy. I like Eli Lilly (LLY) .”

    Cramer and the AAP team note that seven of the companies in their portfolio are reporting this week, including Abbott Laboratories (ABT) , Nucor (NUE) and Honeywell (HON) . Find out what they’re telling their investment club members and get in on the conversation with a free trial subscription to Action Alerts PLUS.

  • [By Lisa Levin] Gainers
    Turtle Beach Corporation (NASDAQ: HEAR) surged 87.1 percent to $12.98 after the company reported Q1 results and raised its FY18 outlook.
    ARMO BioSciences, Inc. (NASDAQ: ARMO) shares jumped 66.8 percent to $49.735 after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share.
    vTv Therapeutics Inc. (NASDAQ: VTVT) gained 34 percent to $2.2920 following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June.
    Prestige Brands Holdings, Inc. (NYSE: PBH) climbed 22.3 percent to $34.84 after the company posted upbeat Q4 earnings.
    Depomed, Inc. (NASDAQ: DEPO) shares jumped 22.2 percent to $7.28 following better-than-expected Q1 earnings.
    Everspin Technologies, Inc. (NASDAQ: MRAM) gained 19.8 percent to $8.89 after the company reported strong results for its first quarter.
    Luxfer Holdings PLC (NYSE: LXFR) surged 19.8 percent to $17.10 following Q1 results.
    Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 18.3 percent to $2.26 after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million.
    Intelligent Systems Corporation (NYSE: INS) gained 17 percent to $7.116.
    Green Dot Corporation (NYSE: GDOT) surged 15.3 percent to $73.00 after reporting upbeat Q1 earnings.
    The Chefs' Warehouse, Inc. (NASDAQ: CHEF) climbed 15 percent to $28.85. Chefs' Warehouse posted Q1 earnings of $0.03 per share on sales of $318.6 million.
    Westport Fuel Systems Inc. (NASDAQ: WPRT) rose 14.2 percent to $2.9701.
    Wright Medical Group N.V. (NASDAQ: WMGI) jumped 13.8 percent to $23.87 after reporting upbeat quarterly earnings.
    Diplomat Pharmacy, Inc. (NYSE: DPLO) gained 13.4 percent to $22.70. Diplomat named Brian Griffin as Chairman and CEO.
    Carvana Co. (NYSE: CVNA) shares rose 13 percent to $27.97 after reporting upbeat Q1 sales.
    Prothena Corporation plc (NASDAQ: PRTA) gained 12 percent to $15.19

3 Biotech Stocks That Soared This Week: Are They Buys?

Sell in May and go away? That old adage would have been horrible advice for investors who owned three biotech stocks that soared over the last week.

ARMO BioSciences (NASDAQ:ARMO), Opko Health (NASDAQ:OPK), and Arrowhead Pharmaceuticals (NASDAQ:ARWR) chalked up huge gains over the last five days. What sent these biotech stocks into orbit? And are they still smart picks for investors? Here’s what you need to know about the fantastic week for ARMO, Opko, and Arrowhead along with what could be next for each stock.

Five test tubes with increasing levels of green liquid from left to right and green arrow drawn behind them curving upward

Image source: Getty Images.

1. ARMO BioSciences: We hardly knew ye

ARMO BioSciences stock skyrocketed 78% this week. The biotech announced on Thursday that it was being acquired by Eli Lilly (NYSE:LLY) for $1.6 billion. What’s especially notable about this acquisition is that ARMO conducted its initial public offering (IPO) less than four months ago.

What made ARMO so attractive to Lilly? The small biotech’s lead product candidate, AM0010, also known as pegilodecakin. AM0010a long-acting form of recombinant humanInterleukin 10(IL-10) that stimulates white blood cells calledCD8+T cells. These T cells recognize and kill cancer cells. The drug is currently being evaluated in a phase 3 study for treatingpancreatic cancer and in earlier-stage studies targeting other types of cancer.

Lilly saw AM0010 as a great addition to its current oncology lineup, which includes Cyramza, Verzenio, and three pipeline candidates in phase 2 clinical studies. The acquisition is expected to close by the end of the second quarter.

2. Opko Health: A Rayaldee of sunshine

Opko Health didn’t see its stock pop as much as ARMO BioSciences, but the biotech did enjoy a big gain of 42% this week. The catalyst for Opko was the company’s better-than-expected first-quarter results announced on Tuesday.

Wall Street analysts expected Opko to report Q1 revenue of nearly $237 million. The company reported revenue of close to $255 million. But while that figure beat what analysts projected, it came in right in line with what Opko’s expectations.

The best news from Opko’s quarterly update for investors was thatchronic kidney disease drug Rayaldee appears to be picking up momentum. Opko stated that Q1 total prescriptions for the drug jumped 731% year over year and were 38% higher than the fourth quarter of 2017. The company also expects that itslaboratory diagnostic business, Bio-Reference Laboratories, will see improvement this year.

3. Arrowhead Pharmaceuticals: Giving more of the silent treatment

Arrowhead Pharmaceuticals stock jumped 38% this week. Although the company announced its Q1 financial results on Tuesday, the bigger story for Arrowhead wasn’t about the top and bottom lines. Instead, investors were encouraged by the biotech’s pipeline updates.

“Target the gene, silence the disease” is Arrowhead’s slogan. The company uses RNA interference (RNAi) to silence gene expression and regulate the production of proteins. This approach allows focused targeting of a wide range of genes and disease pathways that have been difficult to address in the past.

Arrowhead announced this week that it had initiated dosing in two phase 1 clinical studies evaluating RNAi therapies in treating rare genetic diseasealpha-1 antitrypsin de铿ciency and hepatitis B. The company also reported that it plans to submit for European approval to begin clinical studies for two preclinical candidates, ARO-APOC3 and ARO-ANG3, later this year.

Are they buys?

Congratulations to those who already bought ARMO BioSciences stock. For everyone else, though, it’s too late to profit from the biotech.But what about Opko Health and Arrowhead?

It’s great to see Rayaldee begin to gain some traction. Opko also is seeing some growth for its4Kscore blood test for detecting prostate cancer. And new leadership at Bio-Reference Labs could get that ship headed in the right direction. My view on Opko is that it could be a winner over the long run, but for now, I’d rather wait to see additional improvement.

I’m intrigued by Arrowhead, though. Alnylam Pharmaceuticals has already shown that RNA interference can be effective and expects to soon win Food and Drug Administration approval for patisiran in treatinghereditary ATTR amyloidosis. Arrowhead could also be on the right track with its RNAi programs.

The main drawback to Arrowhead is that its pipeline candidates still have a long way to go. Arrowhead is the kind of stock that could make a ton of money — or lose a ton of money — for shareholders. My hunch is that it will be a winner over the long run, but I’m not ready to step out on a limb and call the stock a buy. There’s simply too much risk right now despite a lot of potential for this clinical-stage biotech.